icon-folder.gif   Conference Reports for NATAP  
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
Improved predictive value for sustained immune control in peginterferon (PEGASYS)-treated HBeAg-positive patients using combined HBsAg and HBV DNA levels at week 24
  Reported by Jules Levin
Presented at The 47th Annual Meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain, 18-22 April, 2012
T. Piratvisuth,1 H.L.Y. Chan,2 P. Marcellin,3 C. Wat,4 L. Regep,5 D. Messinger,6 H.-P. Kapprell,7 Z.-M. Lu,8 K.X. Luo9
1NKC Institute of Gastroenterology and Hepatology, Department of Internal Medicine, Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand;2Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; 3Service d'Hepatologie and INSERM CRB3/U773, University Paris-Diderot, Clichy, France; 4Roche Products Limited, Welwyn Garden City, United Kingdom; 5F. Hoffmann-La Roche, Basel, Switzerland; 6IST GmbH, Mannheim, Germany; 7Abbott GmbH and Co. KG, Wiesbaden, Germany; 8Department of Infectious Diseases, Ruijin Hospital, Shanghai, China; 9Department of Infectious Diseases, Nanfang Hospital, Guangzhou, China